Novavax have published preliminary phase 2a-b clinical trial results for their COVID-19 vaccine candidate (NVX-CoV2373), assessing vaccine efficacy against SARS-CoV-2 variants (B.1.351- South African strain). This vaccine candidate is a nanoparticle based vaccine containing pieces of the SARS-CoV-2 spike protein.

In this study, participants aged between 18 and 84 years, received either a 2 dose course of the candidate vaccine or a 2 dose course of a placebo (normal saline). Approximately 30% of participants were seropositive for SARS-CoV-2 prior to commencing the trial. Among the seronegative participants, approximately 94% were HIV-negative and 6% were HIV-positive.

A vaccine efficacy of 49.4% was seen among participants who were seronegative at baseline, regardless of HIV status. In the HIV-negative cohort, vaccine efficacy was 60.1%. A history of previous SARS-CoV-2 infection did not reduce the risk of subsequent infection with the new variants of SARS-CoV-2.

To read the article and view these results in full please refer to the below link:

NEJM: Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant